Air Liquide Healthcare, the company that brought the Tandem t:slim X2 insulin pump to the UK, reports that the roll out of its Control-IQ closed-loop software over a summer limited by lockdown has gone well. Early adopters transferred over from Basal-IQ to Control-IQ over the summer months, with the remainder happening through autumn, following approval from users’ clinics.
Basal-IQ software meant that the t:slim X2 insulin pump could predict a low blood glucose and suspend insulin delivery based on readings from a Dexcom CGM sensor. Control-IQ added in additional insulin delivery being done by the pump on readings of too-high glucose readings. Simon Treadwell, Tandem’s UK Manager says, “There have been great initial results from those who have made the transition from Basal- to Control-IQ, with users reporting increased Time in Range. Due to circumstances, training for the update from Basal-IQ to Control-IQ took place at home instead of the clinic, via virtual consultations and online training modules. In some cases we were able to assist in clinics, but in the main remote upgrades were possible. We even had some entirely new people going on our pumps supported in their own homes by remote video and telephone support. We were also able to provide remote support clinic staff for training on the new software.”
Transition to the newer software was made possible for some by the publishing of the NICE Medtech Innovation Briefing on the Tandem t:slim X2 insulin pump for managing blood glucose levels in Type 1 diabetes. The NICE briefing reports that studies show the t:slim X2 insulin pump, with predictive low-glucose suspend technology or advanced hybrid closed-loop system, is more effective than comparators.
As of the start of October, Control-IQ data will also be visible in the Diasend mobile app for those who use the Diasend platform.
